CA
NZ
UK
AU
IND
US
ViewRay, Inc (OTC:VRAYQ) built its reputation on a genuinely differentiated technology: MRIdian, a system that combines magnetic-resonance imaging with radiation therapy to target tumors in real time. Yet a compelling product did not translate into a durable business, and the company's stock now lingers …
Vistagen Therapeutics (NASDAQ:VTGN)' shares have drifted into penny-stock territory, and the recent weakness follows a pivotal setback for the company's lead anxiety program. The San Carlos, California biopharma built much of its narrative around fasedienol, an investigational intranasal "pherine," and a late-stage clinical miss …
A sleep-medicine company posting double-digit revenue growth would normally command a healthier share price than Vivos Therapeutics, Inc (NASDAQ:VVOS) currently does. Trading below $0.20 in September 2026, the Colorado-based maker of oral appliances for obstructive sleep apnea and related airway disorders is delivering its …
● At a quoted price near $0.0004, that move reflects the arithmetic of extremely low-priced stocks, where the smallest price increment can equal a large percentage of the share price; it is not tied to any confirmed public catalyst.
Vycor Medical, Inc. (OTC:VYCO) is one of those small medical-device companies that rarely generates headlines, and the ticker VYCO has been living up to that reputation in September 2026. Trading over the counter at pennies per share, the Boca Raton, Florida company sits well …
● At a quote of roughly $0.000001, the stock sits at the very bottom of the pricing scale, where a single trade or a stale quote can produce enormous percentage changes that have nothing to do with fresh news.
● The modest single-session decline in WVE shares does not trace to a specific, verifiable public catalyst; small moves like this are common for clinical-stage biotech names and often reflect broad sentiment rather than fresh news.
A screener flagging a dramatic single-day jump can look like a breakout, but for Vincerx Pharma, Inc. (OTC: VINC) the reality is far more sober. The former Nasdaq-listed cancer biotech spent 2025 winding down its operations after two failedMergerattempts, then moved to delist from …
● United American Healthcare oration is the kind of deeply obscure micro-cap where a large percentage move says more about thin trading than about freshBusinessnews.
● The honest answer is that no single, freshly verified catalyst sits behind the stock's recent quiet trading.
Please wait processing your request...